After promising early results, ALS drug moves toward new, larger trial

Infusion therapy aims to allow damaged nerve connections to recover

Written by Patricia Inácio, PhD |

A doctor and patient together look at data on a tablet.

A new study in Australia will test an ALS drug candidate that showed some positive results in an early clinical trial. (Image from iStock)

  • An infusion therapy being developed by Australian researchers aims to slow ALS progression by creating conditions for damaged nerve connections to heal. 
  • The experimental treatment, dubbed NUN-004, showed early signs of effectiveness in eight ALS patients in a small clinical trial.
  • Now, the developer is planning the launch of a larger Phase 2 trial to test the drug's safety and effectiveness.

After showing encouraging early signs of disease stabilization and functional improvements in a small study, an experimental infusion therapy for amyotrophic lateral sclerosis (ALS) is advancing to a new, larger clinical trial in Australia.

Nuerve announced in a company press release that it will test its therapy candidate NUN-004 in a Phase 2 trial (ACTRN12626001318370) spanning about six months. The upcoming trial will investigate whether NUN-004 is superior to a placebo at slowing ALS progression. Approximately 75 people with the progressive neurological disease will be enrolled at six Australian sites.

“No approved treatment has been shown to halt or reverse progression across the broad ALS population,” said Perry Bartlett, PhD, Nunerve’s chairman and chief scientific officer and an emeritus professor at the University of Queensland in Australia. Bartlett’s research was key to developing the drug, according to the biotech.

“NUN-004 was designed to go further to protect motor neurons and create the conditions for damaged neural connections to repair,” Bartlett said. Motor neurons are the specialized nerve cells that control movement and are progressively lost in ALS.

Results from an earlier Phase 1/1b trial (ACTRN12621000514808) showed that NUN-004 was generally well tolerated and associated with a slight improvement in patients’ functional scores during an initial treatment period. That study involved eight people with ALS and 20 healthy volunteers.

Antony Winkel, PhD, Nunerve’s clinical lead, said individuals with ALS “urgently need better treatment options grounded in high-quality evidence.” According to Winkel, also an associate professor at Griffith University in Australia, “this trial combines measures of everyday function with respiratory, neurophysiological and biomarker assessments to determine whether the early Phase 1 signal is a real treatment effect.”

Recommended Reading
A woman sits on a toilet holding her stomach.

Study links constipation with faster ALS progression, poorer survival

In people with ALS, motor neurons gradually die, leading to worsening muscle weakness and eventually affecting walking, speaking, swallowing, and breathing. While some individuals experience slower progression and live with the disease for decades, others can have a relatively rapid decline over a few years.

Long-acting drug aims to suppress key pathway in ALS

NUN-004 is a long-acting, protein-based therapy designed to block the activity of EphA4, a receptor protein involved in nerve cell connections and repair. Excessive EphA4 signaling has been linked to motor neuron degeneration and impaired recovery of damaged nerve connections.

By suppressing this pathway, NUN-004 — administered via infusions to the bloodstream — aims to protect motor neurons and create conditions that allow damaged nerve connections to recover.

In the Phase 1/1b study, the healthy volunteers first received single increasing doses of NUN-004. This was followed by the drug’s use among eight ALS patients who received the therapy once a week in four-week cycles for up to six months. The results showed no serious adverse events, treatment discontinuations, or detectable anti-drug antibody responses.

Among the measures of function assessed was the ALS Functional Rating Scale-Revised (ALSFRS-R), which looks at a person’s ability to perform everyday activities, such as walking, speaking, and swallowing, as well as breathing. Higher scores indicate better function.

During the first four treatment cycles, scores showed a slight improvement, averaging 0.09 points per month. However, across the entire study, scores declined by an average of 0.35 points per month. Changes in forced vital capacity, a measure of lung function, followed similar patterns.

Nunerve also reported patient feedback suggesting improvements in grip, balance, walking, strength, and fatigue.

However, the study involved just eight patients with ALS and had no placebo group, meaning the findings cannot establish whether NUN-004 slowed or reversed disease progression.

In the new Phase 2 trial, participants will be randomly assigned to receive either NUN-004 or a placebo during an initial 24-week period (about six months), with neither patients nor investigators knowing which treatment is being administered. Eligible participants can then enter an open-label extension portion, during which all will receive NUN-004 for 24 weeks.

The main goal is to determine whether the drug slows disease progression, measured by changes in ALSFRS-R scores. Researchers will also evaluate safety, lung function, nerve and muscle activity, quality of life, and biomarkers associated with nerve damage.

Nunerve, established to advance research originating at the University of Queensland’s Queensland Brain Institute, plans to seek additional investment and partnerships to support further development of NUN-004. If the Phase 2 results confirm the preliminary findings, they could support a larger Phase 3 trial, according to the company.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.